Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Achilles Therapeutics (ACHL) yesterday and set a price target of $23.00.
The post Achilles Therapeutics (ACHL) Receives a Buy from Oppenheimer appeared first on Smarter Analyst.
Oppenheimer analyst Mark Breidenbach maintained a Buy ...

https://www.smarteranalyst.com/new-blurbs/achilles-therapeutics-achl-receives-a-buy-from-oppenheimer/

#SmarterAnalyst